

Washington State Pharmacy and Therapeutics Committee / Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, October 19, 2022 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Jordan Storhaug, Committee Chair
9:05 a.m.	Calcitonin Gene-Related Peptide Inhibitors (CGRP) - topic brief <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Sara Kennedy, DERP
9:30 a.m.	Second Generation Antidepressants- surveillance <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Shannon Robalino, DERP
9:55 a.m.	Multiple Sclerosis- surveillance <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Beth Shaw, DERP
10:20 a.m.	Pharmacy & Therapeutics Committee Adjourns Break (10 min)	Jordan Storhaug, Committee Chair All
10:30 a.m.	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Jordan Storhaug, Committee Chair
10:30 a.m.	Antihyperlipidemics <ul style="list-style-type: none"> • Microsomal Triglyceride Transfer Protein (MTP) Inhibitor • PCSK-9 Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:50 a.m.	Antivirals <ul style="list-style-type: none"> • Influenza Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:55 a.m.	Cardiovascular Agents <ul style="list-style-type: none"> • Sinus Node Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11 a.m.	Endocrine And Metabolic Agents <ul style="list-style-type: none"> • Pituitary Suppressants Oncology Agents <ul style="list-style-type: none"> • LHRH Analogs – Injectable 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
11:10 a.m.	Gastrointestinal Agents <ul style="list-style-type: none"> ● Inflammatory Bowel Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:15 a.m.	Gastrointestinal Agents <ul style="list-style-type: none"> ● Irritable Bowel Syndrome (IBS) Agents / GI Motility <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:30 a.m.	Gastrointestinal Agents <ul style="list-style-type: none"> ● Phosphate Binder Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:35 a.m.	Genitourinary Agents <ul style="list-style-type: none"> ● Overactive Bladder Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:40 a.m.	Hematological Agents <ul style="list-style-type: none"> ● Hereditary Angioedema Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:45 a.m.	Miscellaneous Therapeutic Classes <ul style="list-style-type: none"> ● Potassium Removing Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:50 a.m.	Multiple Sclerosis Agents <ul style="list-style-type: none"> ● Stakeholder input* ● Motion 	Umang Patel, Magellan
12:10 p.m.	Lunch (30 min)	All
12:40 p.m.	Substance Use Disorder <ul style="list-style-type: none"> ● Agents For Opioid Withdrawal ● Opioid Antagonists ● Opioid Partial Agonists - Subcutaneous ● Opioid Partial Agonists - Transmucosal <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:00 p.m.	ADHD / Anti-Narcolepsy <ul style="list-style-type: none"> ● Dopamine And Norepinephrine Reuptake Inhibitors (DNRIS) ● Histamine H3-Receptor Antagonist / Inverse Agonist ● Non-Stimulants ● Stimulants - Long Acting ● Stimulants - Misc ● Stimulants - Short Acting <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:20 p.m.	Allergy <ul style="list-style-type: none"> ● Allergenic Extracts / Biologicals - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

1:25 p.m.	Antipsychotics / Antimanic Agents <ul style="list-style-type: none"> • Antipsychotics - 2nd Generation • Antipsychotics - Combinations • Parkinsons Psychotic Disorder <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
2:05 p.m.	Break (10 min)	All
2:15 p.m.	Movement Disorder Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
2:35 p.m.	Glaucoma Agents <ul style="list-style-type: none"> • Adrenergic Agents • Adrenergic Agents Combinations • Beta - Blockers • Beta - Blockers Combinations • Carbonic Anhydrase Inhibitors • Kinase Inhibitors • Miotics • Prostaglandins <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
2:45 p.m.	Ophthalmic Agents <ul style="list-style-type: none"> • Immunomodulators <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
2:50 p.m.	Respiratory Agents <ul style="list-style-type: none"> • Pulmonary Fibrosing Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
3 p.m.	Smoking Deterrents <ul style="list-style-type: none"> • Misc - Other <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
3:05 p.m.	Oncology Agents <ul style="list-style-type: none"> • Androgen Biosynthesis Inhibitors – Oral • Antiandrogens – Oral • Antineoplastics - Misc Combinations – Oral • BRAF Kinase Inhibitors – Oral • Cyclin Dependent Kinases (CDK) Inhibitors – Oral • FGFR Kinase Inhibitors – Oral • Hedgehog Pathway Inhibitors – Oral • MEK Inhibitors – Oral • MTOR Kinase Inhibitors – Oral • Multikinase Inhibitors – Oral • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors – Oral • Retinoids – Oral • Topoisomerase Inhibitors – Oral • Tropomyosin Receptor Kinase Inhibitors – Oral • Tyrosine Kinase Inhibitors – Oral 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
4:00 p.m.	<ul style="list-style-type: none"> ● DUR Board Adjourns 	Jordan Storhaug, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPolicy@hca.wa.gov

** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.